cFMS Receptor Inhibitor II

CAS No. 959860-85-6

cFMS Receptor Inhibitor II( —— )

Catalog No. M20305 CAS No. 959860-85-6

cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 110 In Stock
10MG 178 In Stock
25MG 323 In Stock
50MG 514 In Stock
100MG 737 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    cFMS Receptor Inhibitor II
  • Note
    Research use only, not for human use.
  • Brief Description
    cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor.
  • Description
    cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    CSF1R
  • Recptor
    CSF1R
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    959860-85-6
  • Formula Weight
    368.43
  • Molecular Formula
    C23H20N4O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:83.33 mg/mL?(226.18 mM)
  • SMILES
    Cc1ccc(Nc2c(cnc3cc(ccc23)-c2ccncc2)C(N)=O)cc1C
  • Chemical Name
    4-[(34-Dimethylphenyl)amino]-7-(4-pyridinyl)-3-quinolinecarboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Buckles R E Mock G V . THE PREPARATION OF TIGLIC AND ANGELIC ACIDS AND ESTERS\r?1[J]. The Journal of Organic Chemistry 1950 15(3):680-684.
molnova catalog
related products
  • Chiauranib

    Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects.

  • Edicotinib

    Edicotinib (JNJ 40346527, PRV 6527) is a potent, selective, orally bioavailable CSF-1R inhibitor with IC50 of 3.2 nM; shows weak affinity for KIT and FLT3 (IC50= 20 nM and 190 nM, respectively).

  • Gimsilumab

    Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.